Viking Therapeutics, Inc. Profile Avatar - Palmy Investing

Viking Therapeutics, Inc.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selec…

Biotechnology
US, San Diego [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Viking Therapeutics, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of VKTX's Analysis
CIK: 1607678 CUSIP: 92686J106 ISIN: US92686J1060 LEI: - UEI: -
Secondary Listings
VKTX has no secondary listings inside our databases.